Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry
NCT05880537
This study is recruiting at 4 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- End-Stage Renal Disease
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- LifeNet Health
- Last updated on ClinicalTrials.gov
- September 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Infirmary Heath · Mobile, AL
California · 2
- Olive View - UCLA Medical Center · Sylmar, CA
- Harbor-UCLA Medical Center · Torrance, CA
Virginia · 1
- Sentara Norfolk General Hospital · Norfolk, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.